Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Court May Ask Roche To Pay Amgen 22.5 Percent Mircera Marketing Royalty

This article was originally published in The Pink Sheet Daily

Executive Summary

Preliminary injunction bars launch of Roche’s Mircera; suggests terms to avoid a permanent injunction.

You may also be interested in...



Roche Wins Ruling On Mircera Importation; Court to Hear Injunction Appeal

Although it may not make much difference for its follow-on biologic Mircera (epoetin beta), Roche has won a battle with Amgen that could affirm a layer of intellectual property protection for all follow-on biologics in the U.S

Roche Wins Ruling On Mircera Importation; Court to Hear Injunction Appeal

Although it may not make much difference for its follow-on biologic Mircera (epoetin beta), Roche has won a battle with Amgen that could affirm a layer of intellectual property protection for all follow-on biologics in the U.S

Roche Agrees To Court Conditions For Mircera Launch

Roche says it will price Mircera at or below Epogen and pay Amgen a 22.5 percent royalty; Amgen presses for a permanent injunction against drug’s launch.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel